PL4335517T3 - Podawanie i dawkowanie diaminofenotiazyn - Google Patents
Podawanie i dawkowanie diaminofenotiazynInfo
- Publication number
- PL4335517T3 PL4335517T3 PL23212899.1T PL23212899T PL4335517T3 PL 4335517 T3 PL4335517 T3 PL 4335517T3 PL 23212899 T PL23212899 T PL 23212899T PL 4335517 T3 PL4335517 T3 PL 4335517T3
- Authority
- PL
- Poland
- Prior art keywords
- diaminophenothiazines
- dosage
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/02—Labels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- Composite Materials (AREA)
- Botany (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612863.9A GB201612863D0 (en) | 2016-07-25 | 2016-07-25 | Administration and dosage of diaminophenothiazines |
| GBGB1710382.1A GB201710382D0 (en) | 2017-06-29 | 2017-06-29 | Administration and dosage of Diaminophenothiazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4335517T3 true PL4335517T3 (pl) | 2026-02-16 |
Family
ID=59399428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17743330.7T PL3487505T3 (pl) | 2016-07-25 | 2017-07-25 | Podawanie i dawkowanie diaminofenotiazyn |
| PL23212899.1T PL4335517T3 (pl) | 2016-07-25 | 2017-07-25 | Podawanie i dawkowanie diaminofenotiazyn |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17743330.7T PL3487505T3 (pl) | 2016-07-25 | 2017-07-25 | Podawanie i dawkowanie diaminofenotiazyn |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US11065256B2 (pl) |
| EP (3) | EP4223297A3 (pl) |
| JP (1) | JP7073330B2 (pl) |
| KR (4) | KR102974404B1 (pl) |
| CN (2) | CN116531386A (pl) |
| AU (3) | AU2017301966B2 (pl) |
| CA (1) | CA3031578C (pl) |
| DK (2) | DK3487505T3 (pl) |
| ES (2) | ES3046673T3 (pl) |
| FI (2) | FI4335517T3 (pl) |
| HR (2) | HRP20230628T1 (pl) |
| MX (2) | MX385594B (pl) |
| MY (2) | MY210565A (pl) |
| PL (2) | PL3487505T3 (pl) |
| PT (2) | PT3487505T (pl) |
| SG (1) | SG11201900228YA (pl) |
| SI (2) | SI4335517T1 (pl) |
| WO (1) | WO2018019823A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY162313A (en) | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| BR112021000802A2 (pt) * | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| CN120148902A (zh) | 2018-09-05 | 2025-06-13 | 云顶道卫思诊断中心有限公司 | 神经系统变性疾病的网络方法 |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| ES2992641T3 (en) * | 2020-05-05 | 2024-12-16 | Wista Lab Ltd | Methylthioninium compounds for use in the treatment of hypoxemia |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
| GB202500018D0 (en) | 2025-01-02 | 2025-02-19 | Wista Lab Ltd | Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| EP1509232B1 (en) | 2002-05-31 | 2008-11-19 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| CN104119294B (zh) * | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| DK2004155T3 (en) * | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| DK2853293T3 (en) | 2006-03-29 | 2018-01-22 | Wista Lab Ltd | Thioninium compounds and their use |
| MY162313A (en) | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| AU2008265045B2 (en) * | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| CN101911081A (zh) | 2007-11-05 | 2010-12-08 | 维斯塔实验室有限公司 | 用于临床试验的体系 |
| WO2010078659A1 (en) | 2009-01-12 | 2010-07-15 | Foster Health Inc. | Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions |
| WO2010104375A1 (en) | 2009-03-12 | 2010-09-16 | N.V. Nutricia | Stigmasterol for the treatment of alzheimer's disease |
| KR20170061177A (ko) | 2009-09-24 | 2017-06-02 | 위스타 레보레이토리스 리미티드 | 결정질 메틸티오니늄 클로라이드(메틸렌 블루) 수화물 |
| WO2011036561A2 (en) | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
| DE102010062810B4 (de) | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| ES2655492T3 (es) | 2010-11-30 | 2018-02-20 | Wista Laboratories Ltd. | Formulaciones que comprenden cloruro de metiltioninio |
| KR101888713B1 (ko) * | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| BR112021000802A2 (pt) | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
-
2017
- 2017-07-25 PL PL17743330.7T patent/PL3487505T3/pl unknown
- 2017-07-25 AU AU2017301966A patent/AU2017301966B2/en active Active
- 2017-07-25 EP EP23165202.5A patent/EP4223297A3/en active Pending
- 2017-07-25 HR HRP20230628TT patent/HRP20230628T1/hr unknown
- 2017-07-25 KR KR1020247016105A patent/KR102974404B1/ko active Active
- 2017-07-25 DK DK17743330.7T patent/DK3487505T3/da active
- 2017-07-25 ES ES23212899T patent/ES3046673T3/es active Active
- 2017-07-25 CA CA3031578A patent/CA3031578C/en active Active
- 2017-07-25 MX MX2019000946A patent/MX385594B/es unknown
- 2017-07-25 US US16/320,148 patent/US11065256B2/en active Active
- 2017-07-25 HR HRP20251365TT patent/HRP20251365T1/hr unknown
- 2017-07-25 SG SG11201900228YA patent/SG11201900228YA/en unknown
- 2017-07-25 EP EP23212899.1A patent/EP4335517B8/en active Active
- 2017-07-25 MY MYPI2023002755A patent/MY210565A/en unknown
- 2017-07-25 JP JP2019501700A patent/JP7073330B2/ja active Active
- 2017-07-25 MY MYPI2019000171A patent/MY201804A/en unknown
- 2017-07-25 ES ES17743330T patent/ES2946165T3/es active Active
- 2017-07-25 WO PCT/EP2017/068749 patent/WO2018019823A1/en not_active Ceased
- 2017-07-25 CN CN202310423724.6A patent/CN116531386A/zh active Pending
- 2017-07-25 KR KR1020227042657A patent/KR102592614B1/ko active Active
- 2017-07-25 SI SI201731628T patent/SI4335517T1/sl unknown
- 2017-07-25 FI FIEP23212899.1T patent/FI4335517T3/fi active
- 2017-07-25 KR KR1020197005446A patent/KR102475825B1/ko active Active
- 2017-07-25 KR KR1020237013185A patent/KR20230058533A/ko not_active Ceased
- 2017-07-25 EP EP17743330.7A patent/EP3487505B1/en active Active
- 2017-07-25 DK DK23212899.1T patent/DK4335517T3/da active
- 2017-07-25 SI SI201731376T patent/SI3487505T1/sl unknown
- 2017-07-25 CN CN201780058028.2A patent/CN109789148A/zh active Pending
- 2017-07-25 PT PT177433307T patent/PT3487505T/pt unknown
- 2017-07-25 FI FIEP17743330.7T patent/FI3487505T3/fi active
- 2017-07-25 PL PL23212899.1T patent/PL4335517T3/pl unknown
- 2017-07-25 PT PT232128991T patent/PT4335517T/pt unknown
-
2019
- 2019-01-22 MX MX2021009899A patent/MX2021009899A/es unknown
-
2021
- 2021-06-16 US US17/349,427 patent/US11759469B2/en active Active
-
2022
- 2022-10-07 US US17/961,765 patent/US12128051B2/en active Active
- 2022-12-19 AU AU2022291420A patent/AU2022291420B2/en active Active
-
2023
- 2023-04-06 US US18/131,570 patent/US12310973B2/en active Active
- 2023-05-17 AU AU2023203084A patent/AU2023203084B2/en active Active
-
2025
- 2025-04-23 US US19/187,936 patent/US20250262219A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301322I2 (nl) | Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan | |
| IL258931A (en) | Therapeutic compounds and methods | |
| EP3709912A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| DK4335517T3 (da) | Indgivelse og dosering af diaminofenothiaziner | |
| IL256652A (en) | Therapeutic compositions, combinations, and methods of use | |
| EP3558424A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| IL260383B (en) | Low dose therapeutic treatment | |
| EP3463228A4 (en) | INTRAOCULAR DELIVERY | |
| PL3362084T3 (pl) | Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania | |
| DK3493862T3 (da) | Lægemiddelindgivelsesanordning | |
| HUE047477T2 (hu) | Palbociclib szilárd dózisformái | |
| EP3352757C0 (en) | ADMINISTRATION OF DEUTERIUM-MODIFIED CFTR POTENTIATION AGENTS | |
| EP3302442C0 (en) | DOSAGE FORMS AND THEIR USE | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| IL252172A0 (en) | Expandable drug delivery devices and method of use | |
| DK3278803T3 (da) | Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor | |
| LT3426285T (lt) | Pegilintos urikazės kompozicijos ir dozės | |
| LT2986304T (lt) | Farmacinė kompozicija, gydymo būdai ir jų panaudojimas | |
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| DK3519018T3 (da) | Medikamentadministrationsanordning | |
| DK3496783T3 (da) | Medikamentadministrationsanordning | |
| DK3400045T3 (da) | Medikamentadministrationsanordning | |
| DK3380139T3 (da) | Medikamentadministrationsanordning | |
| EP3310376A4 (en) | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | |
| DK3558438T3 (da) | Lægemiddelindgivelsesanordning |